The biology and clinical implications of prostate cancer dormancy and metastasis

Disseminated tumor cells (dtcs) are detected early in the disease process in prostate cancer (pca) patients and can persist after radical prostatectomy. dtcs can remain dormant in patients with no evidence of disease for a prolonged period of time only to recur 10 or more years later. recent advances in single-cell genomics and transcriptomics have provided much needed insight into dtc biology and cancer dormancy in patients. with the development of new in vitro and preclinical models, researchers recapitulate the clinical events in patients and therefore allow further elucidation of the molecular mechanisms underlying cancer dormancy and escape. in this review, we explore novel ideas on the detection, heterogeneous transcriptomic profiles, molecular and cellular mechanisms of dormancy, and potential mechanisms underlying dormancy escape by dtcs. as such, there is hope that identifying and targeting novel dormancy-associated pathways in patients with residual disease will have significant clinical implications for the treatment of pca patients in the future.